DNA · Ginkgo Bioworks Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Ginkgo reported Q2 2026 revenue of $20 million, down 48% year-over-year, with an Adjusted EBITDA loss of $36 million, while reaffirming full-year cash burn guidance of $125–$150 million. The company secured new autonomous lab contracts at MIT, Caltech, Northwestern, and University of Maryland, and began work on a $47 million EMSL lab at PNNL.
- + Won autonomous lab contracts at four universities, with three (Caltech, Northwestern, Maryland) commissioned under NSF's ~$400 million cloud lab network
- + Began work on a $47 million, 97-instrument autonomous lab for PNNL's EMSL
- + New ADME-One service is priced 10x cheaper than WuXi and signed 17 customers in first 6 weeks
- + Held $302 million in cash, cash equivalents and marketable securities as of June 30, 2026
- − Q2 revenue fell 48% year-over-year to $20 million
- − Q2 Adjusted EBITDA loss widened to $(36) million from $(25) million year-over-year
- − Q2 GAAP net loss from continuing operations widened to $(57) million from $(53) million
- − Q2 cash burn increased to $45 million from $38 million year-over-year
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNA
this stock
Ginkgo Bioworks Holdings, Inc.
|
$577.78M | +50.4% | -25.1% | — | 10.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNA | +22.0% | +77.8% | +93.8% | -2.6% | +50.4% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +22.4% | +78.0% | +81.4% | -2.8% | +38.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.